N. Zealand Biotechs Say Patent-Sale Tax Drives Firms, Jobs Abroad
This article was originally published in PharmAsia News
Executive Summary
New Zealand’s biotech industry is lobbying to modify the nation’s law imposing a tax on the sale of patents, saying it is steering some companies elsewhere.
You may also be interested in...
Pfizer’s Hospira Faces 15-Year Wait On US Adrenalin Generic
Hospira’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Merz Consumer Care Optimistic About Future As German Lockdown Continues
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
Need a specific report? 1000+ reports available
Buy Reports